Fresenius Medical reports Q2 adjusted EPS EUR0.91 vs. EUR0.72 last year

Reports Q2 revenue EUR4.79B vs. EUR4.77B last year. “In Q2 2025, we further improved our operational performance as strong organic revenue growth and double-digit operating income growth put us fully on track to deliver our full year 2025 financial outlook”, said CEO Helen Giza. “Organic revenue growth of 7% was supported by all operating segments. The overall phasing of earnings in the first half of the year developed in line with our planning. Strong profitability gains in Care Enablement led to double-digit operating income growth. Care Delivery also drove improvements in operating income and margin, despite flat U.S. volume development. We remain encouraged by the strong and accelerating momentum in patient referrals that continued in the second quarter. However, this positive development in patient inflow was offset by higher-than-expected patient outflow driven by continued elevated mortality and a greater number of missed treatments following the severe flu season in the first months of the year. In the second half of the year, we expect to realize further significant operational and financial improvements.” Giza added: “Reflecting our confidence and the strong cash generation, we are about to initiate the first tranche of the announced share buyback in August.”